Type 2 Diabetes

Latest Headlines

Latest Headlines

Takeda touts CV data from alogliptin use in high-risk diabetes patients

Takeda Pharmaceutical said a post hoc study on alogliptin showed no increase in the composite rate of cardiovascular mortality and among high-risk patients with diabetes. The results were published in The Lancet.

Lilly submits prasugrel NDA

Eli Lilly and Daiichi Sankyo have submitted the much-watched drug prasugrel to the FDA. The drug--an oral antiplatelet agent--is poised to take on the blockbuster Plavix.

ALSO NOTED: Anemia drugs back in the spotlight; Biodel completes VIAject enrollment; and much more...

> The FDA has revealed two new studies that show cancer patients may be more likely to die while using Amgen's blockbuster drugs Aranesp and Epogen (also sold under the brand name Procrit by

Startup: Syndexa takes flight on Harvard technology

Syndexa Pharmaceuticals is joining the herd in the

Novo: no pancreatitis risk linked to Liraglutide

Hoping to calm worries spark by a recent announcement by the FDA that the diabetes drug Byetta is linked to a higher risk of acute pancreatitis, Novo Nordisk said that there is nothing in its data

SPOTLIGHT: Dara licenses Bayer drugs

DARA BioSciences in Raleigh, NC has licensed in IP and compounds for type 2 diabetes and dyslipidemia from Bayer HealthCare AG. Bayer gets an undisclosed upfront fee along with a schedule of

ALSO NOTED: Novartis teams up with MIT; EMEA approves Galvus; and much more...

> Novartis is teaming up with MIT to develop new ways to manufacture drugs. The company will give the university $65 million over 10 years to create a new research program. Report > Galvus, a

Researcher calls FDA 'shortcuts' into question

A high-profile researcher has issued what is now one of many public challenges to the manner in which the FDA speeds approval of certain drugs. Researcher Dr. Clifford J. Rosen is concerned, in

Metabasis stock tanks on double dose of bad news

Metabasis Therapeutics announced a pair of setbacks on Tuesday, saying that Schering-Plough is pulling out of a collaboration to develop a new therapy for hepatitis B and that an experimental

Press Release: BMS Reports on First Phase II Short-Term Study of Dapagliflozin

Press Release: BMS Reports on First Phase II Short-Term Study of Dapagliflozin